Intra-Cellular Therapies Cash on Hand 2013-2022 | ITCI

Intra-Cellular Therapies cash on hand from 2013 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Intra-Cellular Therapies cash on hand for the quarter ending March 31, 2022 was $0.773B, a 26.07% increase year-over-year.
  • Intra-Cellular Therapies cash on hand for 2021 was $0.414B, a 37.2% decline from 2020.
  • Intra-Cellular Therapies cash on hand for 2020 was $0.659B, a 194.12% increase from 2019.
  • Intra-Cellular Therapies cash on hand for 2019 was $0.224B, a 35.54% decline from 2018.
Intra-Cellular Therapies Annual Cash on Hand
(Millions of US $)
2021 $414
2020 $659
2019 $224
2018 $348
2017 $464
2016 $384
2015 $475
2014 $130
2013 $37
2012 $19
Intra-Cellular Therapies Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $773
2021-12-31 $414
2021-09-30 $479
2021-06-30 $556
2021-03-31 $613
2020-12-31 $659
2020-09-30 $723
2020-06-30 $409
2020-03-31 $450
2019-12-31 $224
2019-09-30 $255
2019-06-30 $285
2019-03-31 $313
2018-12-31 $348
2018-09-30 $376
2018-06-30 $404
2018-03-31 $437
2017-12-31 $464
2017-09-30 $328
2017-06-30 $343
2017-03-31 $368
2016-12-31 $384
2016-09-30 $538
2016-06-30 $443
2016-03-31 $456
2015-12-31 $475
2015-09-30 $511
2015-06-30 $204
2015-03-31 $235
2014-12-31 $130
2014-09-30 $136
2014-06-30 $140
2014-03-31 $146
2013-12-31 $37
2013-09-30 $46
2013-06-30 $0
2013-03-31 $0
2012-12-31
2012-09-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.204B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00